Catalog No.
VHC85101
Species reactivity
Human
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
CD37, Tspan-26, TSPAN26, Leukocyte antigen CD37, Tetraspanin-26
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P11049
Applications
ELISA, FCM, Neutralization, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Iv0275
Note
For research use only. Not suitable for clinical or therapeutic use.
Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia., PMID:27040707
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma., PMID:27416486
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan., PMID:27493270
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate., PMID:27587710
Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment., PMID:27834943
New emerging therapies in the management of chronic lymphocytic leukemia., PMID:27899962
Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia., PMID:27977057
A role for the tetraspanin proteins in Salmonella infection of human macrophages., PMID:28602860
Novel Insights into Membrane Targeting of B Cell Lymphoma., PMID:28718418
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models., PMID:28753442
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan., PMID:28848035
CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy., PMID:28855210
Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies., PMID:29323537
Non-IgE mediated mast cell activation., PMID:29431205
Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study., PMID:29453628
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients., PMID:29470615
Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice., PMID:29551516
Combination of 177 Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma., PMID:29993152
Anti-CD37 targeted immunotherapy of B-Cell malignancies., PMID:30293139
Effect of classical conditioning over immature and mature B lymphocytes regulation., PMID:30365190
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering., PMID:30792198
Blockade pf CD73/adenosine axis improves the therapeutic efficacy of docetaxel in epithelial ovarian cancer., PMID:30941556
Phase 1 first-in-human trial of the anti-CD37 antibody BI 836826 in relapsed/refractory chronic lymphocytic leukemia., PMID:31089249
New drugs for old targets., PMID:31187537
Functional study of 14-3-3 protein epsilon (YWHAE) in keratinocytes: microarray integrating bioinformatics approaches., PMID:31244373
Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003., PMID:31309259
Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine., PMID:31481583
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest., PMID:31836849
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma., PMID:32172489
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003., PMID:32187209
DuoHexaBody-CD37®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies., PMID:32341336
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma., PMID:32474843
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma., PMID:32578153
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma., PMID:32877524
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma., PMID:33196921
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma., PMID:33259039
CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies., PMID:33333768
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:33523334
Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma., PMID:33652767
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia., PMID:33683501
Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel., PMID:34945004
89Zr-PET imaging to predict tumor uptake of 177Lu-NNV003 anti-CD37 radioimmunotherapy in mouse models of B cell lymphoma., PMID:35428777
FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?, PMID:35486292
Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome., PMID:35914223
β-Lapachone Exerts Anticancer Effects by Downregulating p53, Lys-Acetylated Proteins, TrkA, p38 MAPK, SOD1, Caspase-2, CD44 and NPM in Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells., PMID:37373014
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine., PMID:38014209
Proximity-Based Labeling Identifies MHC Class II and CD37 as B Cell Receptor-Proximal Proteins with Immunological Functions., PMID:38625120
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies., PMID:38846084
CD37 in acute myeloid leukemia: a novel surface target for drug delivery., PMID:39348689
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas., PMID:39374583
For research use only. Not for human or drug use.
